Showing results (111-120 of 242) with videos related to
Sort By:
Pageof 25
In Vivo (Athens, Greece)|January 1, 2022
Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell LinesMasahiro Hirata, Koji Fujita, Shintaro Fujihara, et al.Plos One|February 22, 2022
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal modelAsahiro Morishita, Tomoko Tadokoro, Shintaro Fujihara, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2014
Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)Yuichiro Eguchi, Yoichiro Kitajima, Hideyuki Hyogo, et al.Archives of Biochemistry and Biophysics|March 26, 2017
Abnormal lipid/lipoprotein metabolism and high plasma testosterone levels in male but not female aromatase-knockout miceAkiko Amano, Yoshitaka Kondo, Yoshihiro Noda, et al.Journal of Gastroenterology|August 27, 2013
The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver diseaseHiroyoshi Taketani, Yoshio Sumida, Saiyu Tanaka, et al.Circulation. Cardiovascular Interventions|December 4, 2020
A Randomized Trial Evaluating Online 3-Dimensional Optical Frequency Domain Imaging-Guided Percutaneous Coronary Intervention in Bifurcation LesionsYoshinobu Onuma, Norihiro Kogame, Yohei Sotomi, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 1, 2024
HbA1c of 5.8% or higher as the most useful indicator for recommendation of ultrasonography to detect nonalcoholic fatty liver diseaseMiwa Tatsuta, Masafumi Ono, Shungo Kimura, et al.Hepatology International|December 30, 2022
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter studyAsahiro Morishita, Kyoko Oura, Kei Takuma, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 9, 2022
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trialMasafumi Ono, Hironori Hara, Hideyuki Kawashima, et al.Plos One|November 14, 2013
Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver diseaseMotoi Hashiba, Masafumi Ono, Hideyuki Hyogo, et al.Pageof 25